Start Date
November 3, 2017
Primary Completion Date
November 19, 2018
Study Completion Date
November 19, 2018
Topotecan (<=8cc)
In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
Topotecan (>8cc)
In predominantly enhancing mass with a volume of \> 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
Cleveland Multiport Catheter
an investigational device, will be used to deliver the topotecan
Magnetic Resonance Imaging (MRI)
to monitor the infusion of topotecan into the tumor
Lower Does Topotecan
Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
Collaborators (1)
Infuseon Therapeutics, Inc.
INDUSTRY
Michael Vogelbaum, MD, PhD
OTHER